Security
LRMR · Larimar Therapeutics, Inc.
LRMRNASDAQCommon stockCurrentCIK 1374690Updated Sep 26, 2026
Name history
ZAFGEN, INC. · through May 19, 2020ZAFGEN INC · through Nov 3, 2008
LRMR price & chart
Loading TradingView…
NASDAQ:LRMR on TradingView ↗About the company
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 145,842,000Source | 200,225,000Source | 95,935,000Source | 126,405,000Source |
| Property, Plant and Equipment, NetUSD | 622,000Source | 881,000Source | 684,000Source | 831,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 85,412,000Source | 33,218,000Source | 26,749,000Source | 26,825,000Source |
| Assets, CurrentUSD | 142,022,000Source | 195,304,000Source | 90,175,000Source | 120,739,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,170,000Source | 11,850,000Source | 3,385,000Source | 2,311,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,069,000Source | 2,838,000Source | 3,078,000Source | 2,858,000Source |
| Other Assets, NoncurrentUSD | 523,000Source | 596,000Source | 659,000Source | 638,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 67,757,000Source | 28,413,000Source | 14,215,000Source | 15,502,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 83,000Source | 64,000Source | 43,000Source | 43,000Source |
| Retained Earnings (Accumulated Deficit)USD | -434,831,000Source | -269,158,000Source | -188,554,000Source | -151,605,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 54,000Source | 148,000Source | 81,000Source | -31,000Source |
| Stockholders' Equity Attributable to ParentUSD | 78,085,000Source | 171,812,000Source | 81,720,000Source | 110,903,000Source |
| Additional Paid in Capital, Common StockUSD | 512,779,000Source | 440,758,000Source | 270,150,000Source | 262,496,000Source |
| Liabilities and EquityUSD | 145,842,000Source | 200,225,000Source | 95,935,000Source | 126,405,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 64,795,000Source | 24,356,000Source | 9,506,000Source | 10,705,000Source |
| Operating Lease, Liability, CurrentUSD | 1,105,000Source | 1,060,000Source | 837,000Source | 611,000Source |
| Accounts Payable, CurrentUSD | 5,216,000Source | 2,424,000Source | 1,283,000Source | 1,686,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,962,000Source | 4,057,000Source | 4,709,000Source | 4,797,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 58,474,000Source | 20,872,000Source | 7,386,000Source | 8,408,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 136,900,000Source | 183,500,000Source | 86,800,000Source | 118,400,000Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -165,673,000Source | -80,604,000Source | -36,949,000Source | -35,355,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,004,000Source | 8,796,000Source | 7,615,000Source | 6,619,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 2,792,000Source | 1,141,000Source | -403,000Source | 26,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -113,201,000Source | -70,760,000Source | -33,459,000Source | -27,569,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 100,309,000Source | -85,387,000Source | 33,353,000Source | -90,960,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 91,000Source | 515,000Source | 164,000Source | 100,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 65,086,000Source | 161,883,000Source | 30,000Source | 75,257,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 52,194,000Source | 5,736,000Source | -76,000Source | -43,272,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 7,004,000Source | 8,796,000Source | 7,615,000Source | 6,619,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 136,900,000Source | 183,500,000Source | 86,800,000Source | 118,400,000Source |
| DepreciationUSD | 350,000Source | 318,000Source | 311,000Source | 318,000Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 18,273,000Source | 17,612,000Source | 14,088,000Source | 12,276,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -165,673,000Source | -80,604,000Source | -36,949,000Source | -35,355,000Source |
| Nonoperating Income (Expense)USD | 6,824,000Source | 10,286,000Source | 4,809,000Source | 1,171,000Source |
| Operating ExpensesUSD | 172,497,000Source | 90,890,000Source | 41,758,000Source | 36,526,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 500,000Source | 400,000Source | 300,000Source |
| Proceeds from Issuance of Common StockUSD | 65,086,000Source | 161,806,000Source | — | 75,257,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 184,000,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -172,497,000Source | -90,890,000Source | -41,758,000Source | -36,526,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -165,673,000Source | -80,604,000Source | -36,949,000Source | -35,355,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -165,673,000Source | -80,604,000Source | -36,949,000Source | -35,355,000Source |
| Earnings Per Share, BasicUSD per share | — | -1.32Source | -0.84Source | -1.37Source |
| Earnings Per Share, DilutedUSD per share | — | -1.32Source | -0.84Source | -1.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 61,256,084Source | 43,901,241Source | 25,761,394Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 61,256,084Source | 43,901,241Source | 25,761,394Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 18,273,000Source | 17,612,000Source | 14,088,000Source | 12,276,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -165,673,000Source | -80,604,000Source | -36,948,000Source | -35,339,000Source |
| Nonoperating Income (Expense)USD | 6,824,000Source | 10,286,000Source | 4,809,000Source | 1,171,000Source |
| Operating ExpensesUSD | 172,497,000Source | 90,890,000Source | 41,758,000Source | 36,526,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 500,000Source | 400,000Source | 300,000Source |
| Research and Development ExpenseUSD | 154,224,000Source | 73,278,000Source | 27,670,000Source | 24,250,000Source |
Filing attachments
lrmr-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures • High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in sc…
Read attachment ↗lrmr-ex99_2.htm · 8-K · 2026-08-04
EX-99.2 3 lrmr-ex99_2.htm EX-99.2 pro August 2026 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commerc…
Read attachment ↗lrmr-ex99_1.htm · 8-K · 2026-06-29
EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 • Daily nomlabofusp increased and sustained skin FXN levels at 1 year and 18 months; 100% (9/9) of partic…
Read attachment ↗lrmr-ex99_2.htm · 8-K · 2026-06-29
EX-99.2 3 lrmr-ex99_2.htm EX-99.2 pro June 2026 Larimar Therapeutics Nomlabofusp Program Update Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop a…
Read attachment ↗lrmr-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update • Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026 • Cross-species nonclinical findings that support skin frataxin levels as a surrogate endpoint for nomlabofusp program published in peer-re…
Read attachment ↗lrmr-ex99_2.htm · 8-K · 2026-05-14
EX-99.2 3 lrmr-ex99_2.htm EX-99.2 pro May 2026 Larimar Therapeutics Corporate Deck Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop a…
Read attachment ↗